Bullish & Foolish
Full GALT fundamentals All 466 on the Survival Watch

GALTGALECTIN THERAPEUTICS INC.

Is Galectin Therapeutics struggling financially?

Yes, by its own account. Galectin Therapeutics told the SEC on 31 Mar 2026, in Form 10-K, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Mar 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$371.1M
Source filing
10-K 31 Mar 2026
Balance sheet
30 Jun 2026

Cash runway

  • 3months

    If the burn speeds up

    Empty by Sep 2026

  • 6months

    If it eases off

    Empty by Dec 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$13.3M

÷

Cash burned over the last 12 months

$34.0M

What Galectin Therapeutics told the SEC

…agreement with the FDA on trial design, or successfully execute a Phase 3 clinical trial even if we determine to pursue one. We have from time to time faced substantial doubt about our ability to continue as a going concern. In 2025, we experienced net losses of $29.7 million, had no revenue from operations, and used $23.9 million in cash to fund our operations. Although management believes that we have…

GALECTIN THERAPEUTICS INC., Form 10-K, filed 31 Mar 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 47% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt